AU2018278422B2 - Lewy body disease therapeutic agent containing pyrazoloquinoline derivative - Google Patents

Lewy body disease therapeutic agent containing pyrazoloquinoline derivative Download PDF

Info

Publication number
AU2018278422B2
AU2018278422B2 AU2018278422A AU2018278422A AU2018278422B2 AU 2018278422 B2 AU2018278422 B2 AU 2018278422B2 AU 2018278422 A AU2018278422 A AU 2018278422A AU 2018278422 A AU2018278422 A AU 2018278422A AU 2018278422 B2 AU2018278422 B2 AU 2018278422B2
Authority
AU
Australia
Prior art keywords
dementia
lewy body
test
disease
rat
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018278422A
Other languages
English (en)
Other versions
AU2018278422A1 (en
Inventor
Yukio Ishikawa
Mai Miyamoto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eisai R&D Management Co Ltd
Original Assignee
Eisai R&D Management Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Management Co Ltd filed Critical Eisai R&D Management Co Ltd
Publication of AU2018278422A1 publication Critical patent/AU2018278422A1/en
Application granted granted Critical
Publication of AU2018278422B2 publication Critical patent/AU2018278422B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
AU2018278422A 2017-06-01 2018-05-30 Lewy body disease therapeutic agent containing pyrazoloquinoline derivative Active AU2018278422B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762513727P 2017-06-01 2017-06-01
US62/513,727 2017-06-01
PCT/JP2018/020650 WO2018221551A1 (ja) 2017-06-01 2018-05-30 ピラゾロキノリン誘導体を含有するレビー小体病治療剤

Publications (2)

Publication Number Publication Date
AU2018278422A1 AU2018278422A1 (en) 2019-11-21
AU2018278422B2 true AU2018278422B2 (en) 2022-03-17

Family

ID=64456542

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018278422A Active AU2018278422B2 (en) 2017-06-01 2018-05-30 Lewy body disease therapeutic agent containing pyrazoloquinoline derivative

Country Status (13)

Country Link
US (1) US11311530B2 (https=)
EP (1) EP3632438B1 (https=)
JP (1) JP7269875B2 (https=)
KR (1) KR20200010220A (https=)
CN (1) CN110612102A (https=)
AU (1) AU2018278422B2 (https=)
BR (1) BR112019023552A2 (https=)
CA (1) CA3061884A1 (https=)
ES (1) ES2961554T3 (https=)
IL (1) IL270357B2 (https=)
MX (1) MX394435B (https=)
TW (1) TWI784006B (https=)
WO (1) WO2018221551A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
WO2023064857A1 (en) 2021-10-14 2023-04-20 Incyte Corporation Quinoline compounds as inhibitors of kras

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2769980A1 (en) * 2011-10-07 2014-08-27 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivative
EP2982675A1 (en) * 2013-04-05 2016-02-10 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5318759A (en) 1976-08-02 1978-02-21 Nisshin Oil Mills Ltd Method of making fried beancurd
JPH05132484A (ja) 1991-04-26 1993-05-28 Otsuka Pharmaceut Factory Inc ピラゾロキノリン及びピラゾロナフチリジン誘導体
DK0760819T3 (da) 1994-05-24 2000-10-09 Hoffmann La Roche Tricykliske dicarbonylderivater
DE19642591A1 (de) 1996-10-15 1998-04-16 Basf Ag Neue Piperidin-Ketocarbonsäure-Derivate, deren Herstellung und Anwendung
HN2002000317A (es) 2001-11-02 2003-05-21 Pfizer Inhibidores de pde9 para tratamiento de trastornos cardiovasculares
BR0313262A (pt) 2002-08-07 2005-07-12 Mitsubishi Pharma Corp Compostos de dihidropirazolpiridina
DE10238722A1 (de) * 2002-08-23 2004-03-11 Bayer Ag Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse
DE102004004142A1 (de) 2003-05-09 2004-11-25 Bayer Healthcare Ag 6-Cyclylmethyl- und 6-Alkylmethyl-substituierte Pyrazolopyrimidine
RU2426734C2 (ru) 2003-10-03 2011-08-20 Зм Инновейтив Пропертиз Компани Пиразолопиридины и их аналоги
WO2005118583A1 (en) 2004-05-28 2005-12-15 Millennium Pharmaceuticals, Inc. 2, 5-dihydro-pyrazolo`4, 3-c!quinolin-4-ones as chk-1 inhibitors
JP2006045118A (ja) 2004-08-04 2006-02-16 Mochida Pharmaceut Co Ltd 新規ピラゾロキノロン誘導体
CA2622605A1 (en) 2005-09-15 2007-03-22 Aska Pharmaceutical Co., Ltd. Heterocycle compound, and production process and application thereof
CA2671980C (en) 2006-12-13 2015-05-05 Aska Pharmaceutical Co., Ltd. Quinoxaline derivatives
WO2008072778A1 (ja) 2006-12-13 2008-06-19 Aska Pharmaceutical Co., Ltd. 尿路系疾患の処置剤
PT2152712E (pt) 2007-05-11 2012-02-29 Pfizer Compostos amino-heterocíclicos
UA105362C2 (en) 2008-04-02 2014-05-12 Бьорингер Ингельхайм Интернациональ Гмбх 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators
JP5453431B2 (ja) 2008-09-08 2014-03-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピラゾロピリミジン及びｃｎｓ障害の治療のためのそれらの使用
TWI404721B (zh) 2009-01-26 2013-08-11 Pfizer 胺基－雜環化合物
WO2010101230A1 (ja) 2009-03-05 2010-09-10 アステラス製薬株式会社 キノキサリン化合物
PE20120505A1 (es) 2009-03-31 2012-05-09 Boehringer Ingelheim Int Derivados de 1-heterociclil-1,5-dihidro-pirazolo[3,4-d]pirimidin-4-ona como moduladores de pde9a
US8880976B2 (en) 2009-09-25 2014-11-04 Stmicroelectronics, Inc. Method and apparatus for encoding LBA information into the parity of a LDPC system
AP2012006631A0 (en) 2010-08-12 2012-12-31 Boehringer Ingelheim Int 6-Cycloalkyl-1, 5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives and their use as PDE9A inhibitors
RS54834B1 (sr) 2010-09-07 2016-10-31 Astellas Pharma Inc Jedinjenja pirazolokvinolina
US20130040971A1 (en) 2011-02-14 2013-02-14 Boehringer Ingelheim International Gmbh 6-cycloalkyl-pyrazolopyrimidinones for the treatment of cns disorders
PT2573073E (pt) 2011-09-26 2015-02-05 Sanofi Sa Derivados de pirazoloquinolinona, sua preparação e sua utilização terapêutica
JP6042060B2 (ja) 2011-09-26 2016-12-14 サノフイ ピラゾロキノリノン誘導体、その調製および治療上の使用
TW201439091A (zh) 2013-04-05 2014-10-16 Eisai R&D Man Co Ltd 吡啶基吡唑并喹啉化合物
KR20200010211A (ko) 2017-06-01 2020-01-30 에자이 알앤드디 매니지먼트 가부시키가이샤 Pde9 저해제를 포함하는 약제학적 조성물
RU2019135834A (ru) 2017-06-01 2021-07-13 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и донепезила
WO2018221550A1 (ja) 2017-06-01 2018-12-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 ピラゾロキノリン誘導体とメマンチンの併用による認知症治療剤

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2769980A1 (en) * 2011-10-07 2014-08-27 Eisai R&D Management Co., Ltd. Pyrazoloquinoline derivative
EP2982675A1 (en) * 2013-04-05 2016-02-10 Eisai R&D Management Co., Ltd. Salt of pyrazoloquinoline derivative, and crystal thereof

Also Published As

Publication number Publication date
ES2961554T3 (es) 2024-03-12
IL270357A (https=) 2020-02-27
BR112019023552A2 (pt) 2020-06-02
US11311530B2 (en) 2022-04-26
IL270357B2 (en) 2024-02-01
TW201902479A (zh) 2019-01-16
EP3632438B1 (en) 2023-08-23
JP7269875B2 (ja) 2023-05-09
MX394435B (es) 2025-03-12
RU2019135690A (ru) 2021-07-13
EP3632438A4 (en) 2020-12-23
MX2019013397A (es) 2020-02-07
AU2018278422A1 (en) 2019-11-21
WO2018221551A1 (ja) 2018-12-06
IL270357B1 (en) 2023-10-01
TWI784006B (zh) 2022-11-21
JPWO2018221551A1 (ja) 2020-04-02
CN110612102A (zh) 2019-12-24
KR20200010220A (ko) 2020-01-30
CA3061884A1 (en) 2019-10-29
RU2019135690A3 (https=) 2021-08-25
US20200155541A1 (en) 2020-05-21
EP3632438A1 (en) 2020-04-08

Similar Documents

Publication Publication Date Title
Nguyen et al. Sigma-1 receptors and neurodegenerative diseases: towards a hypothesis of sigma-1 receptors as amplifiers of neurodegeneration and neuroprotection
AU2018278422B2 (en) Lewy body disease therapeutic agent containing pyrazoloquinoline derivative
EP3632439B1 (en) Dementia therapeutic agent combining pyrazoloquinoline derivative and donepezil
Garcia-Romeu et al. Psychedelics as novel therapeutics in Alzheimer’s disease: rationale and potential mechanisms
KR102627790B1 (ko) 피라졸로퀴놀린 유도체와 메만틴을 병용한 치매 치료제
EA037187B1 (ru) Способ и композиция для лечения когнитивного расстройства
Chhabra et al. Pre-clinical aspects and contemporary treatments of Parkinson's disease
Saboory et al. The long‐term effects of neonatal morphine administration on the pentylenetetrazol seizure model in rats: The role of hippocampal cholinergic receptors in adulthood
RU2802212C2 (ru) Терапевтическое средство для лечения болезни телец леви, содержащее производное пиразолохинолина
US20030051262A1 (en) Animal models for neurodegenerative disease
CN101678010B (zh) 包含(R)-螺[1-氮杂二环[2.2.2]辛烷-3,2’(3’H)-呋喃并[2,3-b]吡啶](AZD0328)的组合物及其在制备治疗阿耳茨海默氏病、ADHD和认知功能障碍的药物中的用途
WO2015060746A1 (ru) Комбинация для лечения и/или профилактики проявлений психических, когнитивных, поведенческих и неврологических нарушений при органических заболеваниях цнс различного генеза
Cromwell et al. The role of the basal ganglia in the expression of stereotyped, self-injurious behaviors in developmental disorders
Galbo-Thomma et al. EFFECTS OF VARENICLINE AND XANOMELINE ON ETHANOL SELF-ADMINISTRATION IN CYNOMOLGUS MONKEYS
RU2784428C2 (ru) Терапевтическое средство для лечения деменции, представляющее собой комбинацию производного пиразолохинолина и мемантина
Sanjakdar INVESTIGATING THE ROLE OF α6 and α4 CONTAINING NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS IN NICOTINE AND COCAINE CONDITIONED PLACE PREFERENCE TESTS IN MICE.
JINLINGSUN et al. Huperzine A inhibits immediate addictive behavior but not behavioral sensitization following repeated morphine administration in rats
Nguyen et al. Shona Mookerjee, Nidhi Kaushal, and Rae R. Matsumoto
Duveau et al. Pronounced antiepileptic activity of the subtype‐selective GABA

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)